arrow
G

Giulia Galli

kingston university
H指数:30
被引数:2,990

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Thyroid toxicity in lung cancer patients treated with immune-checkpoint inhibitors: a single-center retrospective analysis

免疫检查点抑制剂治疗肺癌患者的甲状腺毒性:一项单中心回顾性分析

2026-04-010
OAAI
APOLLO11: a bio-data-driven model for clinical and translational research in lung cancer

APOLLO11: 用于肺癌临床和转化研究的生物数据驱动模型

2026-01-290
OAAI
Clinicopathological features of mismatch repair-deficient colorectal cancer: an observational experience from Romagna, Italy

错配修复缺陷型结直肠癌的临床病理特征:来自意大利艾米利亚-罗马涅地区的观察经验

2026-01-010
PRE
A non-small cell lung cancer fragile elderly patient treated with immunotherapy and non-ablative radiation therapy: a case report of a winning combination

一例接受免疫疗法和非消融放射治疗的非小细胞肺癌脆弱老年患者:一种获胜组合的病例报告

2025-08-150
OA
Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671)

ramucirumab联合卡铂和紫杉醇治疗未治疗的转移性胸腺癌的疗效和安全性: RELEVENT II期试验 (NCT03921671)

2024-09-012
OA
CT and MRI radiomic features of lung cancer (NSCLC): comparison and software consistency

肺癌 (NSCLC) 的CT和MRI影像特征: 比较和软件一致性

2024-06-172
OAAI
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research
2024-03-011
OAAI
Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients
2023-01-2311
OAAI
PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers

人 (NCT03447678),一线II期pembrolizumab试验,在阴性和低PD-L1晚期NSCLC中: 临床结果和与循环免疫生物标志物的关联

2022-12-015
OAAI
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis

免疫检查点抑制剂单独或联合其他药物治疗实体恶性肿瘤早期死亡风险的比较评估: 系统回顾和荟萃分析

2022-12-01126
PRE
Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer

循环脂肪酸谱作为晚期非小细胞肺癌免疫治疗的生物标志物

2022-11-015
PRE
Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC
2022-09-2010
OAAI
Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center

实体瘤患者的mRNA anti-SARS-CoV-2疫苗接种的功效和体液免疫反应的动态: 来自意大利三级癌症中心的机构注册结果

2022-07-270
OAAI
SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis
2022-05-014
OAAI